647 Background: Few data are available concerning the prognostic and predictive role of CGA in elderly pts ≥70 years with metastatic RCC treated with either Sun or Paz. Materials and Methods: We retrospectively reviewed the charts of all elderly pts with advanced RCC treated at our Institute with either Sun or Paz, with at least 6 months follow-up after starting treatment. Every pt received at baseline a CGA and was classified as fit, vulnerable or frail according to Balducci’s Criteria. Results: We identified 73 pts who started therapy from January 2006 to March 2018, median age 76 years (range 70-89), 63% males; 42.5% fit and 57.5% unfit pts (38.3% vulnerable, 19.2% frail). Sun to Paz ratio was 40 to 33 pts with a median duration of treatment of 10.8 months; incidence of G1/2 toxicities was 85% vs 93.9% (p = 0.28), G3/4 was 37.5% vs 30.3% (p = 0.63), dose reduction was necessary in 77.5% vs 78.8% of pts (p = 0.9), respectively. Median PFS and OS with Sun or Paz were 13.6 vs 9.4 months (p = 0.152) and 27 vs 22.3 months (p = 0.641), respectively. CGA fit category predicted longer PFS (p = 0.039) and OS (p = 0.001) in the whole cohort. We found no significant differences between fit and unfit pts according to incidence of G1/2 adverse events, incidence of dose reduction or necessity to early suspend treatment due to toxicity, while the incidence of G3/4 events was lower in the fit subgroup (p = 0.026). Out of 67 pts progressing after first line therapy, 27 (40.3%) received a second line consisting in Nivolumab (22.4%), Everolimus (13.4%) and Sorafenib (4.5%), while 40 (59.7%) received only palliative treatments. CGA fit category significantly correlated with a higher chance of receiving a second line treatment (p = 0.004). Conclusions: In our retrospective single-center experience, CGA has a strong prognostic value in terms of OS and has the ability to discriminate pts at higher risk of experiencing G3/4 toxicities with Sun or Paz, with shorter PFS and lower chance of receiving a second line treatment. There were no striking differences in terms of toxicity rates between Sun or Paz, although different in type and possibly biased by patient selection.
The Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival with Multiple Myeloma: A Single Center Experience